Underperforming Launches Reflect A New Era Of Payer Headwinds, IQVIA Says
US drug launches are underperforming historical metrics across nearly all therapeutic areas, according to IQVIA, which said limiting payer policies are the key factor.
US drug launches are underperforming historical metrics across nearly all therapeutic areas, according to IQVIA, which said limiting payer policies are the key factor.